COVID-19 Variant Supplement – Neutralizing Antibodies as SARS-CoV-2 Therapeutics

Rini, James M | $50,000

Ontario University of Toronto 2021 CIHR Operating Grant

Three highly virulent coronaviruses – SARS-CoV, MERS-CoV and SARS-CoV-2 – have crossed species barriers to infect humans since 2003. SARS-CoV-2 is responsible for COVID-19, a disease that arose in Wuhan China in December of 2019. The virus has infected over 64,000 people and caused 1380 deaths and the World Health Organization has declared it a public health emergency of international concern. Although drastic measures are being taken to contain SARS-CoV-2, there is an urgent need for new therapeutics to combat this virus and reduce its spread. In this work we will develop therapeutics based on human antibodies that can be used in the treatment of COVID-19.

With funding from the Government of Canada

Please complete this short survey to help us understand our impact. Thank you!

Give Feedback